CoChat

Management of epithelial precancerous conditions and lesions in the stomach (MAPS II): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG), European Society of Pathology (ESP), and Sociedade Portuguesa de Endoscopia Digestiva (SPED) guideline update 2019

Open access
Pimentel-Nunes, Pedro, Libânio, Diogo, Marcos-Pinto, Ricardo, Areia, Miguel, Leja, Marcis, Esposito, Gianluca, Garrido, Monica, Kikuste, Ilze, Megraud, Francis, Matysiak-Budnik, Tamara, Annibale, Bruno, Dumonceau, Jean-Marc, Barros, Rita, Fléjou, Jean-François, Carneiro, Fátima, van Hooft, Jeanin, Kuipers, Ernst, Dinis-Ribeiro, Mario · 2019 · Endoscopy

The DOI matches its Crossref record; 193 of the 195 references it cites were found in a registry or an index.

Abstract

Main Recommendations: Patients with chronic atrophic gastritis or intestinal metaplasia (IM) are at risk for gastric adenocarcinoma. This underscores the importance of diagnosis and risk stratification for these patients. High definition endoscopy with chromoendoscopy (CE) is better than high definition white-light endoscopy alone for this purpose. Virtual CE can guide biopsies for staging atrophic and metaplastic changes and can target neoplastic lesions. Biopsies should be taken from at least two topographic sites (antrum and corpus) and labelled in two separate vials. For patients with mild to moderate atrophy restricted to the antrum there is no evidence to recommend surveillance. In patients with IM at a single location but with a family history of gastric cancer, incomplete IM, or persistent Helicobacter pylori gastritis, endoscopic surveillance with CE and guided biopsies may be considered in 3 years. Patients with advanced stages of atrophic gastritis should be followed up with a high quality endoscopy every 3 years. In patients with dysplasia, in the absence of an endoscopically defined lesion, immediate high quality endoscopic reassessment with CE is recommended. Patients with an endoscopically visible lesion harboring low or high grade dysplasia or carcinoma should undergo staging and treatment. H. pylori eradication heals nonatrophic chronic gastritis, may lead to regression of atrophic gastritis, and reduces the risk of gastric cancer in patients with these conditions, and it is recommended. H. pylori eradication is also recommended for patients with neoplasia after endoscopic therapy. In intermediate to high risk regions, identification and surveillance of patients with precancerous gastric conditions is cost-effective.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1055/a-0859-1883

Cites

193 of 193 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 193 references

Research works printed but not linked: 7

  1. Dinis-Ribeiro M, Areia M, de Vries AC et al. Management of precan- cerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED). Virchows Arch 2012; 460: 19 -46
  2. Laurèn P. The two histological main types of gastric carcinoma: dif- fuse and so-called intestinal-type carcinoma. Acta Pathol Microbiol Scand 1965; 64: 31 -49
  3. Lash JG, Genta RM. Adherence to the Sydney System guidelines in- creases the detection of Helicobacter gastritis and intestinal meta- plasia in 400738 sets of gastric biopsies. Aliment Pharmacol Ther 2013; 38: 424 -431
  4. Schistosomes, liver flukes and Helicobacter pylori. IARC Working Group on the evaluation of carcinogenic risks to hu- mans. Lyon, 7-14 June 1994. IARC Monogr Eval Carcinog Risks Hum 1994; 61: 1 -241
  5. Matsukura N, Onda M, Tokunaga A et al. Mucosal IgA antibody against Helicobacter pylori in chronic gastritis and intestinal meta- plasia detected by the Tes-Tape method in resection specimens after gastrectomy for gastric cancer. Cancer 1995; 75: 1472 -1477
  6. Malfertheiner P, Megraud F, O'Morain CA et al. Management of Heli- cobacter pylori infection -the Maastricht V/Florence Consensus Re- port. Gut 2017; 66: 6 -30
  7. Tian W, Zhao Y, Liu S et al. Meta-analysis on the relationship be- tween nonsteroidal anti-inflammatory drug use and gastric cancer. Eur J Cancer Prev 2010; 19: 288 -298

Cited by

Items 201–300 of 1,000

Metadata

Authors
Pimentel-Nunes, P., Libânio, D., Marcos-Pinto, R., Areia, M., Leja, M., Esposito, G., Garrido, M., Kikuste, I., Megraud, F., Matysiak-Budnik, T., Annibale, B., Dumonceau, J.-M., Barros, R., Fléjou, J.-F., Carneiro, F., van Hooft, J., Kuipers, E., & Dinis-Ribeiro, M.
Affiliations
  • Gastroenterology Department, Portuguese Oncology Institute of Porto, Portugal
  • Universidade do Porto (PT)
  • Center for Research in Health Technologies and Information Systems (CINTESIS), Faculty of Medicine, Porto, Portugal
  • Instituto Português de Oncologia de Coimbra Francisco Gentil (PT)
  • Institute of Clinical and Preventive Medicine, University of Latvia, Digestive Diseases Center, GASTRO, Riga, Latvia
  • Azienda Ospedaliera Sant'Andrea (IT)
  • Department of Gastroenterology, Porto University Hospital Centre, Institute of Biomedical Sciences, University of Porto (ICBAS/UP), Portugal
  • INSERM U1053, Université de Bordeaux and CHU Pellegrin, Laboratoire de Bacteriologie, Bordeaux, France
  • IMAD, Hepato-Gastroenterology and Digestive Oncology, CHU de Nantes, University of Nantes, France
  • Gastroenterología Diagnóstica Terapeútica (AR)
  • Sorbonne Université (FR)
  • Department of Gastroenterology and Hepatology, Amsterdam UMC, University of Amsterdam, The Netherlands
  • Erasmus MC (NL)
Venue
Endoscopy
Published
2019-03-06
Volume
51
Issue
04
Pages
365-388
ISSN
  • 0013-726X (ISSN-L)
  • 1438-8812
OpenAlex
W2921353582
Cited by
993
References
195
Citations by year
2026: 82 · 2025: 126 · 2024: 165 · 2023: 159 · 2022: 153 · 2021: 136 · 2020: 103 · 2019: 55
FWCI
106.64
Type
journal article
Language
en
Open access
Locations
  • Endoscopy (publishedVersion)
  • PubMed (publishedVersion)
  • IRIS Research product catalog (Sapienza University of Rome) (submittedVersion, other-oa)
  • Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
  • EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
  • Pure Amsterdam UMC (submittedVersion, cc-by)
  • Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) (submittedVersion, other-oa)
Topics
  • Health Sciences › Medicine › Gastroenterology › Helicobacter pylori-related gastroenterology studies
  • Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
  • Health Sciences › Medicine › Gastroenterology › Gastrointestinal Bleeding Diagnosis and Treatment
Keywords
gastric precancerous lesions, chronic atrophic gastritis, intestinal metaplasia, gastric dysplasia, gastric adenocarcinoma risk, chromoendoscopy, virtual chromoendoscopy, endoscopic surveillance, Helicobacter pylori eradication, biopsy targeting, risk stratification, gastric cancer screening
MeSH terms
Biopsy, Europe, Gastritis, Atrophic, Humans, Metaplasia, Patient Care Management, Precancerous Conditions, Stomach Neoplasms, Endoscopy, Gastrointestinal, Helicobacter Infections, Risk Assessment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.